Healthy Volunteer Study

23
Pipeline Programs
4
Companies
20
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
23
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
8100%
+ 15 programs with unclassified modality

Competitive Landscape

4 companies ranked by most advanced pipeline stage

Atea Pharmaceuticals
18 programs
18
AT-527Phase 11 trial
AT-527Phase 11 trial
AT-527 550 mg + cyclosporinePhase 11 trial
AT-527 550 mg + midazolamPhase 1
AT-527 Formulation 1Phase 11 trial
+13 more programs
Active Trials
NCT05004415Completed6Est. Aug 2021
NCT04877769Completed24Est. Aug 2021
NCT04849299Completed24Est. May 2021
+12 more trials
Roche
RocheSTAVANGER NORWAY, Norway
3 programs
3
AT-527 550 mg + midazolamPhase 11 trial
Drug: AT-527 + rosuvastatinPhase 1Small Molecule1 trial
Period 1: AT-527 550 mgPhase 11 trial
Active Trials
NCT04865445Completed24Est. May 2021
NCT05154123Completed29Est. Dec 2021
NCT04784000Completed20Est. Apr 2021
AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
1 program
1
AZD8566Phase 11 trial
Active Trials
NCT00866385Completed21Est. Apr 2009
NewAmsterdam Pharma
NewAmsterdam PharmaNARRDEN, Netherlands
1 program
1
Fixed-Dose CombinationPhase 11 trial
Active Trials
NCT06050291CompletedEst. Apr 2024

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Atea PharmaceuticalsEthinyl Estradioll/Levonorgestrel
Atea PharmaceuticalsBuprenorphine/Naloxone + BEM/RZR
Atea PharmaceuticalsTreatment A-Bemnifosbuvir/Ruzasvir FDC administered fasting
Atea PharmaceuticalsBemnifosbuvir
Atea PharmaceuticalsDigoxin vs Digoxin + BEM/RZR vs Digoxin + 2h BEM/RZR
Atea PharmaceuticalsCohort 1: Days 1-7 Bemnifosbuvir
NewAmsterdam PharmaFixed-Dose Combination
Atea PharmaceuticalsBemnifosbuvir
Atea PharmaceuticalsBemnifosbuvir
Atea PharmaceuticalsBemnifosbuvir
Atea PharmaceuticalsCohort 1 BEM + Ruzasvir
Atea PharmaceuticalsAT-527 fasted
RocheDrug: AT-527 + rosuvastatin
Atea PharmaceuticalsAT-527
Atea PharmaceuticalsAT-527

Showing 15 of 20 trials with date data

Clinical Trials (20)

Total enrollment: 229 patients across 20 trials

NCT07272889Atea PharmaceuticalsEthinyl Estradioll/Levonorgestrel

Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Ethinyl Estradiol/Levonorgestrel (EE/LNG)

Start: Dec 2025Est. completion: Dec 2025
Phase 1Not Yet Recruiting
NCT07314346Atea PharmaceuticalsBuprenorphine/Naloxone + BEM/RZR

Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Buprenorphine/Naloxone or Methadone

Start: Dec 2025Est. completion: May 2026
Phase 1Not Yet Recruiting
NCT07007806Atea PharmaceuticalsTreatment A-Bemnifosbuvir/Ruzasvir FDC administered fasting

Drug-drug Interaction Study of Omeprazole and Bemnifosbuvir/Ruzasvir

Start: May 2025Est. completion: Jun 2025
Phase 1Completed

Study of Bemnifosbuvir/Ruzasvir as a Fixed-dose Combination in Subjects With Normal or Severely Impaired Renal or Hepatic Function

Start: Apr 2025Est. completion: Nov 2025
Phase 1Recruiting
NCT06921941Atea PharmaceuticalsDigoxin vs Digoxin + BEM/RZR vs Digoxin + 2h BEM/RZR

Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Digoxin and Rosuvastatin

Start: Apr 2025Est. completion: Jul 2025
Phase 1Completed
NCT06356194Atea PharmaceuticalsCohort 1: Days 1-7 Bemnifosbuvir

Drug-drug Interaction Study of Biktarvy and Bemnifosbuvir/Ruzasvir

Start: Apr 2024Est. completion: May 2024
Phase 1Completed
NCT06050291NewAmsterdam PharmaFixed-Dose Combination

Investigating the Effect of Food on the Bioavailability of a Fixed Dose Combination of Obicetrapib and Ezetimibe

Start: Jan 2024Est. completion: Apr 2024
Phase 1Completed

Pharmacokinetics of Fixed-Dose Combination Tablet of Bemnifosbuvir and Ruzasvir

Start: Dec 2023Est. completion: Aug 2024
Phase 1Completed

The Study of Bemnifosbuvir in Healthy Japanese Subjects

Start: Apr 2023Est. completion: May 2023
Phase 1Completed

Study of Bemnifosbuvir on Cardiac Repolarization in Healthy Subjects

Start: Apr 2023Est. completion: May 2023
Phase 1Completed
NCT05731843Atea PharmaceuticalsCohort 1 BEM + Ruzasvir

Drug-drug Interaction Study of Ruzasvir and Bemnifosbuvir

Start: Jan 2023Est. completion: Mar 2023
Phase 1Completed

Study of AT-527 in Healthy Subjects Under Fasting Conditions or With a Meal

Start: Feb 2022Est. completion: Aug 2022
Phase 1Completed
NCT05154123RocheDrug: AT-527 + rosuvastatin

Drug-drug Interaction Study of Rosuvastatin and AT-527 (R07496998)

Start: Nov 2021Est. completion: Dec 202129 patients
Phase 1Completed

Mass Balance Study of AT-527 in Healthy Adult Male Subjects (R07496998)

Start: Jul 2021Est. completion: Aug 20216 patients
Phase 1Completed

Bronchopulmonary PK of AT-527 (R07496998)

Start: Apr 2021Est. completion: Aug 202124 patients
Phase 1Completed
NCT04865445RocheAT-527 550 mg + midazolam

Drug-drug Interaction Study of Midazolam and AT-527 (R07496998)

Start: Apr 2021Est. completion: May 202124 patients
Phase 1Completed
NCT04849299Atea PharmaceuticalsAT-527 550 mg + cyclosporine

Effect of Cyclosporine on the Pharmacokinetics (PK) of AT-527 (R07496998)

Start: Apr 2021Est. completion: May 202124 patients
Phase 1Completed
NCT04784000RochePeriod 1: AT-527 550 mg

Effect of Carbamazepine on the Pharmacokinetics (PK) of AT-527

Start: Mar 2021Est. completion: Apr 202120 patients
Phase 1Completed

Study of AT-527 in Healthy Subjects (R07496998)

Start: Nov 2020Est. completion: Sep 202181 patients
Phase 1Completed

AZD8566 Food Effect/Microtracer Study

Start: Mar 2009Est. completion: Apr 200921 patients
Phase 1Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 229 patients
4 companies competing in this space